Relenza® [Zanamivir]
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Relenza is an antiviral agent. Highly inhibits neuraminidase - a surface enzyme of the influenza virus, incl. all known subtypes of neuraminidase of influenza A virus, blocks the replication of influenza viruses A and B. It prevents the release of new virus particles from infected cells, the interaction of viruses with the surface of the epithelial cells of the respiratory tract and their infection.
Indications
Prevention and treatment of influenza A and B in adults and children over 5 years.
Composition
1 dose contains zanamivir 5 mg, as well as lactose as a filler.
No customer reviews for the moment.
Dosage and Administration
Inhalation, using a special device "Relenza Diskhaler."
Treatment: 2 inhalations (5 mg x 2) 2 times a day for 5 days (maximum daily dose - 20 mg); treatment is recommended to begin within the first two days of the disease.
Prevention: 2 inhalations (5 mg x 2) 1 time per day for 10 days (maximum daily dose - 10 mg).
Adverse reactions
Very rarely - bronchospasm, shortness of breath, allergic reactions (including rash, urticaria, swelling of the face and the mucous membrane of the oropharynx).
Contraindications
Hypersensitivity to the drug.
Drug interactions
Do not combine with other inhaled drugs (including bronchodilators).
Pregnancy and Lactation
Contraindicated in the first trimester of pregnancy, in the second and third trimesters it is possible if the expected effect of therapy outweighs the potential risk to the fetus. At the time of treatment should stop breastfeeding.
Special instructions
If bronchospasm develops, inhalation should be stopped immediately and consult a doctor. If you have a history of respiratory diseases accompanied by bronchospasm, you should carry bronchodilators (for example, salbutamol) during the entire period of treatment.
Overdosage
Accidental overdose is unlikely due to metered administration, route of administration and low bioavailability of the drug.
With inhalation use of 64 mg / day (more than 3 times the recommended daily dose), no side effects have been registered. Also, they are not registered with parenteral use of the drug Relenza at a dose of 1.2 g / day. within 5 days.
- Brand name: Relenza
- Active ingredient: Zanamivir
- Dosage form: Powder for inhalation.
- Manufacturer: GlaxoSmithKline
- Country of Origin: Great Britain
Studies and clinical trials of Relief (Click to expand)
- Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities
- Synthesis of novel analogues of zanamivir as neuraminidase inhibitors
- Oseltamivir and zanamivir are effective for treating influenza, but preventive effects are unclear
- Determination of zanamivir in rat and monkey plasma by positive ion hydrophilic interaction chromatography (HILIC)/tandem mass spectrometry
- A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B
- Oseltamivir, zanamivir and amantadine in the prevention of influenza: A systematic review
- Computational analysis and modeling the effectiveness of ‘Zanamivir’ targeting neuraminidase protein in pandemic H1N1 strains
- Scheduling workforce relief breaks in advance versus in real-time
- Two randomized, double-blind, placebo-controlled efficacy studies assessing the efficacy and speed of onset of pain relief of Panadol Advance® in post-surgical dental pain
- Judgments. Equitable Relief. Enforcement of Judgment for Advance Payments on Contract of Sale Repudiated by Buyer
- Advance relief under the Cape Town Convention
- Advance relief under the Cape Town Convention and its Aircraft Protocol: A comment on Gilles Cuniberti's interpretative proposal
- Pain Relief - From Analgesics to Alternative Therapies || Advance Delivery System Dosage Form for Analgesic, Their Rationale, and Specialty
- PCEA compared to continuous epidural infusion in an ultra-low-dose regimen for labor pain relief: a randomized study
- Modifications du relief cutané provoquées par le rayonnement ultra-violet
- Quasi-Contractual Relief under Executory Ultra Vires Contracts
- ECS Transactions [ECS Semiconductor Technology for Ultra Large Scale Integrated Circuits and Thin Film Transistors 3 - Hong Kong, China (June 26 - July 1, 2011)] - (Invited) Short Channel Effects and Drain Field Relief Architectures in Polysilicon TFTs
- Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief
- PCEA Compared to Continuous Epidural Infusion in an Ultra-Low-Dose Regimen for Labor Pain Relief: A Randomized Study
- Effects of Ultra-Low-Dose Buprenorphine on Suicidal Ideation Confounded by Physical Pain Relief?
- Ultra–low-dose Naloxone as an Adjuvant to Patient Controlled Analgesia (PCA) With Morphine for Postoperative Pain Relief Following Lumber Discectomy
- On Residual Stress and Relief for an Ultra-Thick Cylinder Weld Joint Based on Mixed Hardening Model: Numerical and Experimental Studies
- Running shoes for relief of plantar pressure in diabetic patients
- Drainage Density and Relative Relief in Humid Steep Mountains with Frequent Slope Failure
- ChemInform Abstract: Novel Inhibitors of Influenza Sialidases Related to Zanamivir. Heterocyclic Replacements of the Glycerol Side-Chain.
- ChemInform Abstract: Dihydropyrancarboxamides Related to Zanamivir: A New Series of Inhibitors of Influenza Virus Sialidases. Part 2. Crystallographic and Molecular Modeling Study of Complexes of 4-Amino-4H-pyran-6-carboxamides and Sialidase from Influenza Virus Types A and B.
- ChemInform Abstract: Sialidase Inhibitors Related to Zanamivir: Synthesis and Biological Evaluation of 4H-Pyran 6-Ether and Ketone.
- ChemInform Abstract: Sialidase Inhibitors Related to Zanamivir. Further SAR Studies of 4-Amino-4H-pyran-2-carboxylic Acid-6-propylamides.
- Synthesis and Antiinfluenza Virus Activity of 7-O-Alkylated Derivatives Related to Zanamivir.